TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03161470

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Repositioning
Description: It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mechanical Chair Repositioning
Description: It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
Study: NCT01620138

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pasireotide
Description: The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.~The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cabergoline
Description: The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.~The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months.
Study: NCT01962103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel 120-270 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: IV infusion
Study: NCT00030901

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-selenomethionine
Description: Randomization between active L-selenomethionine and placebo
Study: NCT03760107

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 2
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 3
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 4
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 5
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect Smokers to Treatment 6
Description: Using a factorial experimental design, the investigators evaluate how coupling a population-based, direct mail intervention with (1) financial incentives and (2) proactive telephone outreach influences connections to evidence-based tobacco treatment services among low-SES smokers.
Study: NCT01533272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir, emtricitabine, maraviroc
Description: experimental drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir, emtricitabine, lopinavir/r
Description: Lopinavir/r 400mg BID
Study: NCT01303874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Description: ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: ETN-matching placebo SC injections once weekly and MTX orally once weekly.
Study: NCT01255722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iobitridol
Description: single IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iopromide
Description: Single IV injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: iomeprol
Description: Single IV injection
Study: NCT04624061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated HIV/HTN care model
Description: The intervention is a multi-component intervention of combined HIV and HTN care, based on the PRECEDE framework, to continuously identify barriers and facilitators leads to better health outcomes including dual control of HIV/HTN among adults in HIV care in the intervention compared to control facilities
Study: NCT03239795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Advertisement
Description: Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
Study: NCT03387852

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for dupilumab
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for dupilumab
Description: Pharmaceutical form: Solution for Injection, Route of administration: SC
Study: NCT04178551

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation Facilitation
Description: The foundation of CONDUIT's implementation activities are the structured interactions between external facilitation teams and internal facilitation teams. A core set of internal facilitation activities will be used across all facilitation teams, and external facilitation teams will use additional activities based on the needs of their sites or clinical settings.
Study: NCT02730819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Illuminate Cream
Description: Topical compound applied daily
Study: NCT04321720

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3-g mustard footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 36 g mustard flour (3 g per l), followed by a ten-minute post-intervention rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-g mustard footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 72 g mustard flour (6 g per l), followed by a ten-minute post-intervention rest period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-g mustard footbath
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C) and 144 g mustard flour (12 g per l), followed by a ten-minute post-intervention rest period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Warm water only
Description: A ten-minute pre-intervention rest period followed by a 20-minute footbath with 12 l of warm water (40 °C), followed by a ten-minute post-intervention rest period.
Study: NCT02345512

Intervention type: DEVICE
Group type: OTHER
Intervention: Lycra Splinting Garment
Description: Wearing of lycra splinting garment for 6 weeks
Study: NCT01433198

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aquatic training
Description: Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
Study: NCT03235583

Intervention type: DEVICE
Group type: OTHER
Intervention: MOTIONPODTM device validation
Description: MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
Study: NCT00714168

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Behavioral Weight Loss Program
Description: This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepped-Care Weight Loss Program
Description: In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
Study: NCT03478891

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOMAB092-00-AB (MAb114)
Description: VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOMAB092-00-AB (MAb114)
Description: VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-EBOMAB092-00-AB (MAb114)
Description: VRC-EBOMAB092-00-AB (MAb114) is a human immunoglobulin (IgG1) monoclonal antibody (MAb) targeted to the Zaire ebolavirus (EBOV) glycoprotein (GP).
Study: NCT00901290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: monophasic oral contraceptive
Description: mg, oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7325
Description: mg, oral dose
Study: NCT02997566

Intervention type: OTHER
Intervention: Autonomic evaluation

Intervention type: OTHER
Intervention: Autonomic evaluation
Study: NCT00502125

Intervention type: PROCEDURE
Intervention: Reflectance Confocal Imaging
Description: A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
Study: NCT02099006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Description: Topical application of the drug at a 2% concentration in combination with 2% Baclofen
Study: NCT00030901

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-selenomethionine placebo
Description: Randomization between active L-selenomethionine and placebo
Study: NCT05148130

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l; 1-hour plasma glucose ≥10.0mmol/l; 2-hour plasma glucose 8.5-11.0 mmol/l. Those women diagnosed with diabetes or pre-diabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.

Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Description: GDM should be diagnosed at any time in pregnancy if one or more of the listed criteria are met following a 75-gram glucose load: fasting plasma glucose ≥5.1 mmol/l; 1-hour plasma glucose ≥10.0mmol/l; 2-hour plasma glucose 8.5-11.0 mmol/l. Those women diagnosed with diabetes or pre-diabetes (impaired fasting glucose or impaired glucose tolerance) before pregnancy were excluded from the study.
Study: NCT04421066

Intervention type: PROCEDURE
Intervention: Gingival and bone sample collection
Description: Gingival and bone samples will be collected from the sites affected by peri-implantitis during their surgical treatment of peri-implantitis or histological and epigenetic analysis.

Intervention type: PROCEDURE
Intervention: Healthy individuals
Description: Gingival and bone samples will be collected from the extraction sites for histological and epigenetic analysis.
Study: NCT01604954

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrient-label
Description: A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Nutrient-label
Description: A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calorie-label
Description: A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Calorie-label
Description: A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No label
Description: Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: No label
Description: Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
Study: NCT01893983

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Coaching
Description: Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
Study: NCT02134691

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Applied Relaxation
Study: NCT04929171

Intervention type: OTHER
Intervention: Physical Therapy
Description: Physical therapy for chronic upper quarter myofascial pain syndrome, as prescribed by the patients' physicians
Study: NCT02872545

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rest tomoscintigraphy in forward tilted
Description: Rest tomoscintigraphy in forward tilted position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rest tomoscintigraphy in forward tilted
Description: Rest tomoscintigraphy in forward tilted position
Study: NCT01538056

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fenestrated Endovascular Graft or Company Manufactured Terumo Aortic Fenestrated TREO Endovascular Graft
Description: PMEG endovascular graft with fenestrations or the Company Manufactured Terumo Aortic Fenestrated TREO Abdominal Stent Graft System to allow for blood flow to vital visceral vessels such as the renal arteries, celiac, and SMA (Superior Mesenteric Artery).
Study: NCT04440579

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Tibial Nerve Stimulation (PTNS)
Description: PTNS is neuromodulation that uses electricity to stimulate the nervous system, specifically the posterior tibial nerve, and is minimally invasive.
Study: NCT02872545

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rest tomoscintigraphy in forward tilted
Description: Rest tomoscintigraphy in forward tilted position

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rest tomoscintigraphy in semi sitting position
Description: Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rest tomoscintigraphy in semi sitting position
Description: Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Rest tomoscintigraphy in dorsal decubitus position
Description: Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
Study: NCT02099006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Used topically at 2% concentration in combination with 2% amitriptyline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoprofen
Description: To be applied topically at a 10% concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: To be applied topically at a 10% concentration
Study: NCT02872545

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rest tomoscintigraphy in dorsal decubitus position
Description: Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
Study: NCT03559010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norgestrel 0.075 mg tablets
Description: All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take one Norgestrel 0.075 mg tablet daily up to 16 weeks.~Subjects will use the investigational product based on their understanding of the directions on the outer packaging called the Drug Facts Label and information inside the product packaging called the Consumer Information Leaflet.
Study: NCT00293826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 50mg via SC (subcutaneous) injection every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 250mg via SC (subcutaneous) injection every 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 108
Description: 125mg via SC (subcutaneous) injection every 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo via SC (subcutaneous) injection every 4 weeks
Study: NCT03417531

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Supplement
Description: Predosed protein powder; can be added to various dishes and drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein Supplement
Description: Predosed protein powder; can be added to various dishes and drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein-free Supplement
Description: Predosed protein-free powder; can be added to various dishes and drinks

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Protein-free Supplement
Description: Predosed protein-free powder; can be added to various dishes and drinks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Exercise
Description: Program includes five strength exercises that can be easily performed at home

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Exercise
Description: Program includes five strength exercises that can be easily performed at home

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control Exercise
Description: Program includes five flexibility exercises that can be easily performed at home
Study: NCT02099006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loperamide
Description: To be applied topically at a 5% concentration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: To be applied topically at a 6% concentration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Compounding base to be used alone as a placebo
Study: NCT03417531

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control Exercise
Description: Program includes five flexibility exercises that can be easily performed at home
Study: NCT04427514

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine software for data transmission and analysis in CAPD.
Description: Telemedicine software is related to peritoneal dialysis. With the help of a tablet device running an Android system on patients and the care team and the smart devices attached to it (scales, blood pressure monitor), patients perform measurements in their homes in connection with solution changes. The resulting data is transmitted through the telemedicine system to the care team, which can take immediate intervention if necessary and notify the patient of any change in therapy.
Study: NCT03503227

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: daily oral low dose prednisolone (10 mg/day) :a glucocorticoid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl Salicylic acid
Description: daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetyl Salicylic acid
Description: daily oral low dose Acetylsalicylic acid (75 mg) : Antiplatelet agent
Study: NCT04273633

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monopolar 448 kilohertz radiofrequency stimulation
Description: 448kilohertz capacitive resistive monopolar radiofrequency will be applied on the dominant shoulder
Study: NCT03145610

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: triclosan/copolymer/fluoride toothpaste
Description: During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.